<DOC>
	<DOC>NCT02562729</DOC>
	<brief_summary>The purpose of this study is to evaluate the feasibility of complete nerve-sparing type C1 radical hysterectomy in cervical cancer.</brief_summary>
	<brief_title>Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer</brief_title>
	<detailed_description>The primary objective of this study is to evaluate the rate of postvoid residual urine volume (PVR) &lt;50ml on postoperative day 4 in patients with stage IB1 and IIA1 cervix cancer underwent complete nerve-sparing type C1 radical hysterectomy.</detailed_description>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age &gt;=18 years to &lt;= 70 years. Women with histologically confirmed, primary adenocarcinoma or squamous cell carcinoma of the uterine cervix. Stage IIA1, or IB1 disease. Karnofsky performance status &gt;70. Patients who comply with followup. With written informed consent. Age&gt;70 History of lower urinary tract damage or surgery. With abnormal urodynamic study results. Karnofsky performance status &lt;70. Patients who have uncontrolled psychological disorders. Unwilling to or unable to comply with protocol. Prior treatment with pelvic radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cervical cancer; Nerve-sparing hysterectomy; simplified</keyword>
</DOC>